Cardiomyopathy secondary prevention

Jump to navigation Jump to search

Cardiomyopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiomyopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Guidelines

2023 ESC Guideline Recommendations

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy

Case Studies

Case #1

Cardiomyopathy secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiomyopathy secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiomyopathy secondary prevention

CDC on Cardiomyopathy secondary prevention

Cardiomyopathy secondary prevention in the news

Blogs on Cardiomyopathy secondary prevention

Directions to Hospitals Treating Cardiomyopathy

Risk calculators and risk factors for Cardiomyopathy secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Lina Ya'qoub, MD; Edzel Lorraine Co, DMD, MD[2]

ICD placement is also recommended for secondary prevention in patients who survived sustained ventricular tachycardia or ventricular fibrillation.

References

Template:WH Template:WS Template:CALISKAN, K. , SZILI‐TOROK, T. , THEUNS, D. A., KARDOS, A. , GELEIJNSE, M. L., BALK, A. H., VAN DOMBURG, R. T., JORDAENS, L. and SIMOONS, M. L. (2011), Indications and Outcome of Implantable Cardioverter‐Defibrillators for Primary and Secondary Prophy